Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis
Background Advances in targeted therapies have expanded the treatment options for colorectal cancer (CRC), allowing for more tailored and effective approaches to managing the disease. In targeted therapy, Bevacizumab is a commonly prescribed anti-VEGF monoclonal antibody that has a direct anti-vascu...
Shranjeno v:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2024-12-01
|
| Serija: | Journal of Pharmaceutical Policy and Practice |
| Teme: | |
| Online dostop: | https://www.tandfonline.com/doi/10.1080/20523211.2024.2354300 |
| Oznake: |
Brez oznak, prvi označite!
|